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Andrographis paniculata decreases fatigue
in patients with relapsing-remitting
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Abstract
Background: Andrographis paniculata (A. paniculata), a medicinal plant, has shown anti-inflammatory, neuroprotective
and antifibrotic effects in animal models as well as clinical efficacy in different studies, including an anti-fatigue effect in
autoimmune diseases such as rheumatoid arthritis. In multiple sclerosis (MS), fatigue is rated as one of the most
common and disabling symptoms. In the present trial, we investigated the effect of A. paniculata on relapse rate and
fatigue in relapsing-remitting MS (RRMS) patients receiving interferon beta.
Methods: A randomised double-blind placebo-controlled trial assessed the effects of 170 mg of A. paniculata dried
extract tablet b.i.d. p.o. on relapse rate and fatigue using the Fatigue Severity Scores (FSS) over 12 months in RRMS
patients receiving interferon. The Expanded Disability Status Scale (EDSS) score, inflammatory parameters and
radiological findings were also investigated. Twenty-five patients were enrolled, and twenty-two patients were
ultimately analysed and randomised to the active or placebo group.
Results: Patients treated with A. paniculata showed a significant reduction in their FSS score as compared to the
placebo, equivalent to a 44 % reduction at 12 months. No statistically significant differences were observed for relapse
rate, EDSS or inflammatory parameters, with a trend in reducing new lesions among the A. paniculata group. One
patient in the A. paniculata group presented with a mild and transient skin rash, which was alleviated with
anti-histamine treatment for three weeks.
Conclusion: A. paniculata was well tolerated in patients and no changes in clinical parameters were observed.
A. paniculata significantly reduces fatigue in patients with RRMS receiving interferon beta in comparison to
placebo and only interferon beta treatment.
Trial registration: ClinicalTrials.gov Identifier: NCT02280876; Trial registration date: 20.10.2014.
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Background
Multiple sclerosis (MS) is an autoimmune disease char-
acterised by inflammation and neurodegeneration within
the central nervous system (CNS). Its development
seems to be multifactorial, with genetic predisposition
influenced by environmental factors. It represents the
main cause of non-traumatic neurological disability in
the young adult population (20–40 years) [1].
Fatigue is defined as “a subjective lack of physical or
mental energy that is perceived by the individual or care-
giver to interfere with usual and desired activities” [1].
Fatigue is rated as one of the most common and disab-
ling symptoms in MS and other autoimmune diseases.
Its prevalence ranges from 65 to 97 % among MS pa-
tients, and it tends to seriously impair approximately
one-third of them, with 55 % describing it as one of the
worst symptoms they experience [2]. Fatigue has a sig-
nificant impact on patients’ quality of life, affecting per-
formance at work as well as their social and private lives
[3]. Fatigue has also been associated with cognitive dys-
function [4, 5] and sleep disorders [6, 7]. Using func-
tional magnetic resonance imaging, it has been proposed
that a dysfunction of critical cortical areas contributes to
the occurrence of central fatigue [8].
Despite many investigations, the pathophysiology
underlying MS-related fatigue is not yet clear. Proposed
mechanisms for fatigue include primary causes such as
grey matter atrophy [9, 10], demyelination and axonal
loss [11], functional cortical reorganisation [12], neuro-
endocrine deregulation [13] and immune system dys-
function and systemic inflammation [14]. Until now, no
pharmacological treatment has shown marked efficacy in
fatigue alleviation [2]. Recently, alfacalcidol treatment
has shown promising effects in the reduction of fatigue
in MS patients [15].
Andrographis paniculata (A. paniculata) is a native
medicinal plant from Southeast Asia. A. paniculata ex-
tracts have been used in autoimmune diseases including
rheumatoid arthritis and ulcerative colitis with some de-
gree of success [16–19]. Many studies indicate that
andrographolide, the main labdane diterpene present in
A. paniculata, is responsible for the reduction of innate
and adaptive immune responses [20–22]. Additionally,
other studies have suggested that andrographolide might
exert neuroprotective effects, that is, effects against
damage induced by dopamine in mesencephalic neuron-
glial cultures associated with a protective effect on
inflammation-mediated neurodegeneration [23], oxida-
tive stress induced by nicotine in the brain [24] and
cerebral ischemia [25].
Animal studies have shown that andrographolide ame-
liorates the symptoms of experimental autoimmune en-
cephalomyelitis (EAE) by interfering with the inductive
phase of EAE [22], which is accomplished by inhibiting
T cell and antibody responses directed to myelin anti-
gens and interference with the maturation of dendritic
cells (DCs) and their ability to present antigens to T
cells. Furthermore, in mdx mice that shows muscular fi-
brosis and physical weakness, andrographolide induces
an increase in exercise endurance [26]. In a previous
placebo-controlled clinical pilot study in patients with
rheumatoid arthritis, A. paniculata was able to signifi-
cantly reduce fatigue after 90 days of treatment versus
the placebo [16]. All this background information sug-
gests a potential use for andrographolide and/or A. pani-
culata in MS patients.
On the other hand, the active compounds of A. pani-
culata have shown low toxicity, as reported by different
clinical studies. The most common adverse event pre-
sented in some isolated cases is the development of mild
skin rash [19], probably associated with andrographolide
or its metabolites. It disappears upon withdrawal of the
drug.
In the present pilot study, we show evidence that a
purified extract of A. paniculata is able to significantly
reduce fatigue in patients with RRMS receiving inter-
feron at 12 months.
Methods
Trial design
This pilot study was a randomised, double-blind,
placebo-controlled, single-site study conducted at the
Regional Hospital of Valdivia, Neurology Department,
Faculty of Medicine of the Universidad Austral de Chile
to evaluate the effect of A. paniculata in RRMS patients
treated with interferon beta.
The trial was conducted in accordance with the
International Conference on Harmonisation Guidelines for
Good Clinical Practice and Applicable Local Regulations, as
well as the Declaration of Helsinki. The Chilean Ministry of
Health, Ethical Scientific Committee of the Health Service
of Valdivia and the local Ethics Committee approved the
clinical protocol. All participants signed informed consent
forms. The trial was registered on ClinicalTrials.gov:
NCT02280876. The diagnostic criteria for MS were in
accordance with MacDonald 2010 [27]. As far as possible,
the CONSORT 2010 guidelines for reporting parallel
group randomised trials were followed [28].
Participant
Inclusion criteria: (a) age between 18 and 50 years
(inclusive), (b) relapsing-remitting MS, (c) Expanded
Disability Status Scale (EDSS) score ≤ 6.0 (due to public
health regulations, patients with EDSS >6 are not allowed
to begin any disease-modifying drug), (d) at least one re-
lapse documented in the previous two years, (e) treatment
with interferon beta-1a [intramuscular (Avonex®) once a
week or subcutaneous (Rebif®) three times a week].
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Exclusion criteria: (a) previous immunosuppressive
treatment (e.g., rituximab, mitoxantrone, cyclophospha-
mide), (b) pregnancy, breastfeeding or absence of effect-
ive contraception, (e) uncontrolled systemic diseases or
a life-threatening and/or unstable clinical condition and/
or alcohol or drug abuse, and (f ) psychiatric disorders
that could affect treatment compliance.
Withdrawal causes from study included: (a) relapse
that needed treatment with corticosteroids; (b) necessity
of second line drugs, immunosuppressive treatment or
plasmapheresis; (c) pregnancy; (d) serious systemic dis-
ease; and (e) voluntary abandonment. If a mild relapse
(i.e., only sensory symptoms) occurred during the study,
the subject was offered the possibility to re-consent and
continue with the protocol.
To assess similarities between the baseline clinical
characteristics of the patients treated with A. paniculata
and the placebo group, a Mann–Whitney U test was
carried out. No statistical differences existed between
the groups (Table 1).
Patients were assigned to two neurologists who were
blind to the patients’ treatment. One physician was re-
sponsible for the clinical aspects of patient care, includ-
ing the evaluation and management of adverse events
and acute relapses. The other physician rated patients
EDSS and FSS scores, and was also blind to patients
symptomatology.
Patients were examined every three months for a
period of 12 consecutive months. In case of a suspected
relapse (new or worsening neurologic symptoms not as-
sociated with fever or infection that lasted at least 24 h
and were accompanied by new objective neurologic
signs), the patient would be referred to the rater neur-
ologist, who would confirm or dismiss the relapse. At
the discretion of the treating neurologist, relapses would
be treated with intravenous methylprednisolone at a
dose of 1000 mg per day for three consecutive days, and
patients would be withdrawn.
Intervention
Eligible patients were randomised to orally receive one
tablet containing 170 mg of A. paniculata purified ex-
tract (total andrographolides: 85 mg per tablet) or pla-
cebo every 12 h for 12 consecutive months, which was
estimated according to previous clinical trials [16].
Both formulations comply with “Good Manufacturing
Practice” and the norms N° 04/2009 from the Institute of
Public Health of Chile (IPH-Chile). The product was
authorised and registered as an Investigational New Drug
(IND), dated 07-30-2013 for IPH-Chile and numbered
2390. The herbal medicine intervention used in this trial
was a highly purified composition of standardised dried
extract of A. paniculata (Burm. f.) Wall. ex Nees
(Acanthaceae). The extract of A. paniculata was provided
by Innobioscience Spa, Chile and manufactured by
EUROlab® laboratories Chile, in blister packs (10 units
each) containing film-coated circular tablets with soft con-
vex surfaces, and blue colour weighing 650 mg in carton
boxes for a month of treatment (60 units). The placebo
was manufactured with the same characteristics and pack-
aging as the active drug, containing only excipients.
The drugs were kept according to the instructions of
the manufacturer and separated from the hospital’s nor-
mal stocks. The extract was obtained from leaves and
aerial parts of A. paniculata that had been kindly
provided by InnoBioscience, LLC (Miami, USA). The
active product tested was a standardised dried extract
of A. paniculata. The extraction procedure was per-
formed with alcohol (75 % ethanol), and the ratio of
herbal drug to extract was 10:1. A botanist identified the
plant. The batch number of A. paniculata extract
used in this study was PAR-130101-7. A voucher spe-
cimen was conserved (no. 20050520) and kept at
InnoBioscience Spa (Miami, USA). The posology was
established according to previous clinical trials [16, 29].
The percentages of quantified chemical constituents per
tablet was as follows: 85 mg of total andrographolides
Table 1 Baseline clinical and radiological characteristics of patients after randomisation in A. paniculata and placebo treatment groups
Parameter A. paniculata n = 13 Placebo n = 11
Mean SD min max Mean SD min max p-value
Age 35.09 11.79 15 47 38.70 10.65 22 51 0.3066
Sex (w/m) 9/4 7/4 0.5250
Disease duration prior to study (year) 3.62 4.56 0 16 6.00 8.20 0 24 0.8067
Relapse (2 years) 1.73 1.27 1 5 1.46 0.52 1 2 0.9236
EDSS 2.64 1.29 1 5 2.08 1.66 0 6 0.1663
FSS 4,15 1,88 1 6.4 3.76 1.68 1 5.5 0.3990
Gd lesion number 0 0
Interferon-beta 1a im.(Avonex® 30 mcg) 7 5
Interferon-beta 1a sc.(Rebif® 44 mcg) 6 6
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(50 % w/w), which were comprised of approximately
3 % w/w of 14-deoxyandrographolide and 0.2 % w/w
of neoandrographolide.
A chemical fingerprint for the extract of A. paniculata
was performed. The method of analysis was as follows:
The compounds were extracted with acetone (4:1) and
then analysed by high-performance liquid chromatog-
raphy (HPLC) using a reverse-phase RP-C18 licrospher
column (4 × 125 mm). The mobile phase was 26 %
acetonitrile and 0.5 % phosphoric acid, eluted at a rate
of 1.1 ml/min, using a wavelength of 228 nm according
to Burgos et al. [30]. The product sample is also kept at
the Laboratory of Pharmacology, University Austral of
Chile. The following reference standards were used:
andrographolide (98 %) purchased from Sigma (St.
Louis, MO) and 14-deoxyandrographolide (90 %) and
neoandrographolide (90 %) supplied by Indena SpA
(Milano, Italy). The purity of these reference standards
was assumed as provided by the suppliers. The placebo
tablets used in this trial were identical in size (lactose
powder filling) and colour (with food colouring) to the
A. paniculata tablets.
Outcomes
The primary outcome of the trial was to evaluate the
efficacy of A. paniculata on fatigue in a group of RRMS
patients receiving interferon beta in a period of
12 months. Fatigue was measured by the FSS score using
a self-rating questionnaire, a reliable and validated nine-
item statement concerning respondents’ fatigue, includ-
ing how fatigue affects motivation; exercise; physical
functioning; carrying out duties; and work, family or
social life. The scale was a seven-point Likert scale,
where 1 = ‘strongly disagree’ and 7 = ‘strongly agree’.
Sum responses are divided by the number of items for
scale score, with a range of 1 to 7, where higher scores
indicate more severe fatigue, with a mean value of 2.3
(SD ± 0.7) in normal healthy adults [31].
Secondary outcomes including other clinical parame-
ters included the relapse rate assessed by the treating
neurologist and confirmed by the EDSS rater, which was
defined as the appearance of new symptoms or the re-
turn of old symptoms for a period of 24 h or more in
the absence of a change in core body temperature or
infection. In addition, safety, tolerability and adverse
events, including a symptom diary where patients could
record any untoward symptom, were recorded. Magnetic
resonances, including T2-FLAIR and T1 pre- and post-
gadolinium (0.1 mmol/Kg), were also performed at base-
line and after 12 months of therapy, and the number of
T2- and gadolinium-enhancing lesions were assessed at
these time points. Plasmatic inflammatory activity pa-
rameters (cytokines) in groups treated with A. panicu-
lata and placebo were also measured.
Treating neurologists were instructed to report any ad-
verse experience, including duration, severity, action
taken, relationship to the study drug and outcome of the
event. Patients were also encouraged to report any ad-
verse event in their symptom diary.
Randomisation, allocation concealment and blinding
All appointments for the 25 participants were arranged
at the Neurology Department of Regional Hospital,
Valdivia, Chile. Twenty-four patients met the inclusion
criteria and were randomised into active or placebo
groups based on the order of their chosen date and the
arrival time for their clinical assessment. These were
assigned to each treatment through a random sampling
design using balanced blocks. A total of 12 placebo and
13 active patients were allocated to each group, accord-
ing to the study statistician’s computer-generated alloca-
tion sequence. Participants were not informed of their
group assignment code. Patient assignments were gener-
ated with the statistical and epidemiology data analysis
software EPIDAT 3.1 [32].
The study physicians did not share their own exam-
ination results, did not handle the study products and
did not know the assigned treatment. Two envelopes
contained each individual’s treatment assignment; one
set was for the Neurology Department to keep for
emergency care and the other was kept with the
Principal Investigator. The two envelopes remained
sealed until data analysis. The appearance of the test
product and placebo-coated tablets was identical, and
no aroma was detected from either. Achievement of
blindness was validated before the trial in a group of
15 volunteers.
Statistical analysis
Sample size was calculated using G*Power 3.1. The
primary endpoint decrease of FSS score considered
the four repeated measurements during one year of
treatment, a size effect of 25 % as shown in a previ-
ous study [16], a 5 % error (alpha) and a potency of
80 %, with two groups and a correlation between the
repeated measurements of 0.3. This resulted in a
sample size of 24 patients.
The distribution probability of the scores was ana-
lysed with the Shapiro–Wilk test; evaluation of the
normality of the data was performed using Graph Pad
PRISM v6. In order to assess the effect of A. paniculata
on the FSS and EDSS scores, a generalised linear mixed
model (GLMM) analysis was performed. Treatment
(A. paniculata and placebo), age (in years), sex (male,
female) and time (four evaluations every three months)
were considered to be fixed effects and patients were in-
cluded as random effect. The GLMM analysis was done
using R software [33].
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Results
The flow chart of the study is depicted in Fig. 1. Demo-
graphic parameters of the two groups included in the
study are shown in Table 1.
In the placebo group, one patient did not complete
the follow-up period and was excluded in the analysis
due to pregnancy. In the A. paniculata group, two
patients did not complete the follow-up period due to
a change in the interferon treatment, which had been
recommended by the study neurologists. Placebo 6/11
and A. paniculata 9/13 were fatigued according to
the cut-off of 4.
Effect of A. paniculata on relapse rate
No relapses occurred in the A. paniculata or placebo
group during the 12-month protocol.
Effect of A. paniculata on FSS score
Overall, a reduction in FSS score was detected across
time. No differences were detected between placebo
and treatment; however, an interaction was detected
between time and treatment, recording a reduction in
FSS score when comparing the initial score (time 0)
in the placebo group with the FSS score induced by
A. paniculata after one year of treatment. The mean
decrease in FSS score was 1.6, and ranged from 1.03
to 2.21 in a period of one year. In contrast, for the
placebo group, the mean decrease in FSS score was
0.43 and ranged from 0.16 to 0.73 in a period of one
year. Patients treated with A. paniculata showed a
significant reduction in the FSS score compared to the
placebo, equivalent to a 44 % reduction at 12 months
(Fig. 2).
Effect of A. paniculata on EDSS score
The EDSS score during the total period of treatment
was similar for the A. paniculata and the placebo
groups, and no significant differences were observed
(Fig. 3). The GLMM analysis revealed that the A. pani-
culata group did not show a significant reduction of
EDSS score compared to time 0. We found no differ-
ences within the placebo group.
Fig. 1 Flow chart of the 12-month double-blind placebo-controlled pilot study
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Effect of A. paniculata in magnetic resonance imaging
(MRI)
Four patients within the placebo group showed new T2
lesions (mean 1; range 0–1), and new gadolinium-
enhancing lesions (mean 1; range 0–1) at 12 months,
compared to baseline MRI. In the A. paniculata group,
only one patient showed one new T2 and one
gadolinium-enhancing lesion.
Safety
Only one patient in the A. paniculata group presented a
mild and transient skin rash, which was alleviated with
anti-histamine treatment for three weeks. The formula-
tion was well tolerated and no changes in clinical param-
eters were observed.
Discussion
In this placebo-controlled double-blind pilot study, we
observed that A. paniculata treatment showed a signifi-
cant reduction of 44 % in the FSS score compared to
placebo at 12 months, and this effect seemed to be time
dependent. As a symptom that highly impacts quality of
life with high emotional, social and employment costs,
the reduction of fatigue by A. paniculata treatment in
MS was considered to be clinically meaningful. No effect
of A. paniculata treatment on EDSS score was observed.
Since EDSS does not include any aspects of fatigue, this
result was expected.
Several pharmacological treatments available for fa-
tigue in people with MS have failed to show clinical effi-
cacy. A recently published comprehensive meta-analysis
included seven clinical trials evaluating different medica-
tions used for the management of fatigue in MS patients.
The authors found weak and inconclusive beneficial
effects of pharmacological intervention limited to
amantadine and Modafinil for MS-related fatigue,
with small and non-significant pooled effect sizes, and
a relatively narrow 95 % CI (pooled effect sizes = 0.07,
95 % CI: −0.22 to −0.37, p = 0.63) [34]. A previous
systematic review that included the effects of amantadine
and pemoline on MS fatigue also reported similar results
[35]. Other comprehensive systematic reviews assessing
the efficacy of 10 different studies on non-specific fatigue
in palliative care investigating amantadine (n = 6), pemo-
line and Modafinil in MS patients [36] showed mixed re-
sults with weak and inconclusive data. Amantadine was
found to demonstrate some improvement in fatigue in
MS patients (meta-analysis of three-studies; standard
mean difference compared to placebo, OR 1.68). Both
pemoline and Modafinil failed to demonstrate a significant
effect for management of fatigue in MS patients [15, 36].
In a randomised double-blind crossover clinical trial, pa-
tients treated with amantadine had their mean (SD) FSS
decrease from 4.8 (1.4) to 4.0 (1.4) (P < 0 · 001), while pa-
tients treated with aspirin had their mean (SD) FSS de-
crease from 4.6 (1.4) to 3.5 (1.5) (P < 0 · 001), suggesting
that both aspirin and amantadine significantly reduce
MS-related fatigue [37]. The discrepancy of results
could be related to the presence of confounders. A
relationship has been proposed between MS-related
fatigue and sleep disorders; moreover, treatment of
underlying sleep disorder has led to an improvement
of MS-related fatigue, and therefore should be consid-
ered as a relevant confounder [7].
Recently, alfacalcidol, a vitamin D analogue, has been
shown to be able to decrease the mean FSS score
Fig. 2 FSS score is reduced in RRMS patients treated with A. paniculata
compared to placebo during one year. Each point represents an
individual score of patients measured at 0, 90, 180 and 360 days.
A box-and-whisker plot with the minimum, 25th percentile, median,
75th percentile, and maximum values are depicted
Fig. 3 EDSS scores in RRMS patients treated with A. paniculata and
placebo during one year. Each point represents an individual score
of patients measured at 0, 90, 180 and 360 days. A box-and-whisker
plot with the minimum, 25th percentile, median, 75th percentile,
and maximum values are depicted
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compared to placebo (−41.6 % vs.−27.4 %, p = 0.007,
respectively) and improve quality of life in MS pa-
tients [15].
Our results suggest that treatment with A. paniculata
could be an effective pharmacological intervention in
the mitigation of fatigue in RRMS patients treated
with interferon beta. The mechanism of action by
which A. paniculata exerts its effect in reducing fa-
tigue is still unknown. Some evidence suggests that
immunological factors, such as elevated levels of pro-
inflammatory cytokines, may contribute to subjective
fatigue in MS patients [38]. The main active com-
pound of A. paniculata, andrographolide, can exert
anti-inflammatory effects, [21, 39, 40] reducing pro-
inflammatory cytokines, e.g., IFNγ [20, 41]. The assess-
ment of cytokine profiles in MS patients with fatigue
treated with A. paniculata should be considered.
Moreover, a direct effect of andrographolide in the
CNS in the control of fatigue cannot be disregarded.
Andrographolide is an apolar compound of low molecu-
lar weight that crosses the blood–brain barrier [42] and
exerts neuroprotective effects [25].
The present study has limitations. For example,
there was a small sample size, which was in part fine-
tuned by the fact that we used a longitudinal study
with repetitive measurements in time. However, in
order to demonstrate the potential effect of A. pani-
culata on fatigue, a new study with a larger number
of patients for a longer period of time (two years),
the assessment of sleep disorders and the use of an
additional fatigue scale differentiating between phys-
ical and cognitive fatigue, e.g., Fatigue Scale for
Motor and Cognitive Functions (FSMC) [43], should
also be considered.
Conclusion
A. paniculata treatment shows a reduction in fatigue at
one year in patients with RRMS receiving interferon beta
in comparison to placebo and only interferon beta treat-
ment. A. paniculata was safe and well tolerated, and no
changes in clinical parameters were observed. Our sam-
ple size was limited, and we failed to achieve the neces-
sary number of recruited patients for some parameters,
specifically for the EDSS score. Indeed, a larger study
including different scales and patient-oriented out-
comes will be required to better determine the effect
of A. paniculata on MS-related fatigue in patients
with RRMS treated with interferon.
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